Dr. Rock is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5518 Lincoln St
Bethesda, MD 20817Phone+1 609-356-9459Fax+1 240-514-3878
Education & Training
Stanford University School of MedicineClass of 1998
Certifications & Licensure
PA State Medical License 2002 - 2014
Publications & Presentations
PubMed
- 62 citationsRole of Fcγ receptors in HER2-targeted breast cancer therapy.Antonino Musolino, William J Gradishar, Hope S Rugo, Jeffrey L Nordstrom, Edwin P Rock
Journal for Immunotherapy of Cancer. 2022-01-01 - 206 citationsEfficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial.Hope S. Rugo, Seock-Ah Im, Fatima Cardoso, Javier Cortes, Giuseppe Curigliano
JAMA Oncology. 2021-04-01 - 41 citationsA First‐in‐Human Phase I Study of OPB‐111077, a Small‐Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced CancersAnthony W. Tolcher, Keith T. Flaherty, Geoffrey I. Shapiro, Jordan Berlin, Thomas E. Witzig
The Oncologist. 2018-06-01
Press Mentions
GlycoMimetics Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia Presented at ASH Annual MeetingDecember 12th, 2022- GlycoMimetics Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia Will Be Presented at ASH Annual MeetingNovember 3rd, 2022
- Partner Therapeutics (PTx) Announces the Appointment of Ed Rock as Chief Medical OfficerSeptember 15th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
